ABCL (AbCellera Biologics) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABCL AbCellera Biologics Inc ABCL
59 GF Score
Price $6.74
GF Value $5.33
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is AbCellera Biologics Short-term investments?

Short-term investments only applies to insurance companies.

ABCL
59GF Score
AbCellera Biologics Inc ABCL
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $6.74 is trading 26.5% above its estimated GF Value™ of $5.33. GuruFocus considers AbCellera Biologics to be Modestly Overvalued.

Key valuation signals for ABCL:

  • Short-term investments:
  • GF Value™: $5.33 vs. price of $6.74 (26.5% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score

Get the complete analysis for ABCL

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.74
Price
$5.33
GF Value